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Population-Based Case-Control Study
on Cancer Screening
by Tomotaka Sobue,* Takaichiro Suzuki,* Isaburo
Fujimoto,* Nobuko yokoi,t and Tsuguo Naruke*
Matched case-control studies have recently been used to evaluate the effectiveness ofcancer screening.
They enable us to estimate the odds ratios of dying of cancer or of getting invasive cancer. The study
compares people with various patterns of screening history with those who were not screened. Criteria
for eligible cases, controls, and screening histories that are compared as exposures are discussed. The
results from a case-control study for evaluating screening for cervical cancer are shown as an example.
Also, a study design of a case-control study for evaluating lung cancer screening in Japan is discussed,
along with biases and applications of case-control studies in evaluating cancer screening.
Introduction
In order to evaluate the effectiveness of cancer
screening, various types of approaches have been de-
veloped (Table 1). As recommended in the 1983 Union
Internationale Contre le Cancer (UICC) workshop, a
randomized controlled trial should be the first choice
(1). However, such a trial is sometimes difficult to con-
duct because of financial or ethical problems or timing
in conducting the study (2). In these situations, nonex-
perimental studiesshouldbechosen, althoughtheinter-
pretation of the results should be carefully checked in
terms ofvarioustypesofbiases. Nonexperimental stud-
ies canbe divided intotwo groups. Oneisagroup-based
Table 1. Classification of approaches for evaluating
cancer screening.
Experimental study (randomized controlled trial)
Nonexperimental study
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comparison between areas with different screening in-
tensity. In these studies, a comparison can be done be-
fore and after the screening is introduced in the same
population or between different areas with different
screening intensities. Also, the correlation can be cal-
culated between screening intensity and mortality or
the incidence ofthe cancer. The other type ofapproach
is an individual-based comparison between people
screened and those who were not. In this type ofstudy,
either a prospective or retrospective approach can be
applied, case-control studies fall into this category.
A case-control study was first applied to the evalu-
ation ofcervical cancer in Toronto (3). Since then, sev-
eral case-control studies have been conducted for eval-
uating cervical cancer (4-7), breast cancer (8-10),
stomach cancer (11), and lung cancer (12). Methodolog-
ical problems have been discussed in terms ofthe def-
inition ofthe cases, controls, and exposures to be com-
pared (13-16).
Definition of Cases, Controls, and
Exposures
Before discussing the criteria for eligible cases and
controls, it is necessary to define what outcomes should
be measured when evaluating the effectiveness of can-
cer screening (15). When most of the cancers that are
detected by screening are invasive cancers, the aim of
the screening is to reduce the mortality of the cancer.
In this case, the mortality ofthe cancer is the outcome.
Screening for cancers of the breast, lung, and most of
the other malignancies can be classified as this type.
On the otherhand, when most ofthe cancers that are
detected by screening are preinvasive cancers, the aim
ofthescreeningistoreducetheincidenceoftheinvasiveSOBUE ETAL.
cancer as well as to reduce the mortality ofthe cancer.
In this case, the incidence ofthe invasive cancer as well
as the mortality can be the outcome to be measured. If
the incidence of the invasive cancer is used, it can be
measured earlier than the mortality, and also lead time
bias andlengthbias canbe avoided. Screeningforcervi-
cal cancer and stomach cancer can be classified as this
type.
Inamatched case-control studyforevaluating cancer
screening, case series should include all deaths or all
patients ofinvasive cancer in a defined population, and
controls should be chosen from anyone at risk of the
cancer in the same population who was alive with no
previous diagnosis of the cancer at the time of the di-
agnosis ofthe matched case. Controls chosen from the
patients with early stage disease, or people who died
at the same time as the case, will not be appropriate;
theseselectionshavealreadybeendiscussedinprevious
papers (13-15). In order to ensure the comparability
between case and controls, it is necessary to match for
the time period in which the screening histories were
compared, as well as sex, age, and other confounding
factors. According to the type of outcome measured,
twokindsofsituationshavetobeconsidered separately.
When using mortality of the cancer as the outcome,
screening histories should be compared between case
and controls up to the time of diagnosis of the case,
including the screening that led to the diagnosis ofthe
case (Fig. 1). Therefore, if a patient is detected by
screeningandthendiedofthe cancer, he orsheisclassi-
fied as screeningpositive. Ifapatient is diagnosed with
cancerin the early stages and thoughttobe cured, then
he or she can be a control as long as the criteria for
eligibility are satisfied. The period to compare the
screening histories can be the full period from the time
when screening started, or a defined period, such as 2
years or 10 years, backwards from the time diagnosing
the case. The number ofyears since the last screening
test and the number ofscreening tests within a defined
period can also be used as exposure variables.
When using the incidence of invasive cancer as the
outcome, two kinds of cases should be considered sep-
arately according to how the cases were detected: one
is prevalent cases, detected by screening, and the other
is incident cases, detected by symptoms. For prevalent
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FIGURE 1. Definition of exposure when mortality is used as out-
come. Includes all screening tests performed up to the time of
diagnosis of the matched case, including the test that led to the
diagnosis ofthe matched case.
screened at the time ofdiagnosis ofthe case, as shown
in Figure 2. This matching ensures that controls are
chosen from those people who do not have preinvasive
cancer. Screening histories should be compared up to
thetimeofdiagnosisofthecase, excludingthescreening
that led to the diagnosis of the case because it is used
formatching. The period inwhichto compare screening
historiescanbedefinedasthatwhenmortalitywasused
as the outcome. It is better to limit the screening his-
toriestothosethatresulted asnegativeifthe specificity
ofthe screening test is considerably high.
On the otherhand, forincident cases, controls should
be chosenfromthosewhowerenotscreened atthetime
ofdiagnosis ofthe case (Fig. 3). This isbecause incident
cases were not screened at the time oftheir diagnoses
by definition, so controls also should be chosen from
those who were not screened at the time ofdiagnosing
the case. Screening histories should be compared up to
thetimeofdiagnosisofthecase, excludingthescreening
that led to diagnosing the case, just as for prevalent
cases.
A typical tabular presentation ofthe result obtained
in a case-control study for evaluating cancer screening
is shown in Table 2. The odds ratio should be calculated
using matched analysis (17). If other confounding fac-
tors that are not used as matching factors have to be
controlled, an analysisbyconditionallogisticregression
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FIGURE 2. Definition ofexposure when incidence ofinvasive cancer
is used as outcome (prevalent case). Includes all screening tests
performed up to the time of diagnosis of the matched case, ex-
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FIGURE 3. Definition ofexposure when incidence ofinvasive cancer
is used as outcome (incident case). Includes all screening tests
performed up to the time of diagnosis of the matched case, ex-
cluding the test that led to the diagnosis of the matched case.
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Table 2. Presentation in a case-control study for evaluating
cancer screening.
Number ofcontrols screened in each matched set
Case 0 1 2 .N Total
Screened mO ml m2 .mN m
Not screened nO nl n2 .nN n
Table 3. Results of cervical cancer screening in Nose Town,
Japan, 1965-1987.a
Person-year of
women over 30 Person-year Screening rate,
Period years of age ofcases %
1965-1969 13,460 689 5.1
1970-1974 14,639 1,336 9.1
1975-1979 15,188 1,170 7.7
1980-1983 13,099 1,060 8.1
1984-1987 13,933 1,859 13.3
aFrom Sobue et al. (18).
Table 4. Age distribution of cervical cancer cases.a
Incidence
Ageb Invasive CISC Mortality'
30-39 3(1)e 3(3) 0
40-49 8(5) 2(2) 1
50-59 7(0) 3(2) 4
60-69 5(0) 0(0) 5
70-79 5(1) 0(0) 5(1)
Total 28(7) 8(7) 15(1)
aFrom Sobue et al. (18).
bAge at the time ofdiagnosis.
cCIS, carcinoma in situ.
dObserved up to February 1, 1988.
eScreen-detected cases in parentheses.
Results from a Case-Control Study
for Evaluating Cervical Cancer
Screening in Osaka, Japan
Nose Town, located in the northern rural area of
Osaka Prefecture, has a highly stable population of
about 10,000. Cervical cancer screening has been con-
ducted in Nose Town since 1965. Table 3 shows both
the person-year of women 30 years of age or more and
the person-year of persons screened and the screening
rate in Nose Town in a 4- or 5-year period. Screening
rates were less than 10% until 1983, and they increased
to 13% between 1984 and 1987. In order to evaluate the
effectiveness ofthe cervical cancer screening program,
a case-control study was conducted.
Table 4 shows the age distribution ofall cervical can-
cer cases and those who died ofthe disease. There were
no deaths in carcinoma in situ cases up to February 1,
1988. Cases who were under 29 years old or over 80
years old were excluded. There were 28 patients with
invasive cancers and 15 patients had died of cervical
cancer; thesepatients wereused as case series. Controls
were chosen fromthosewho were alivewith noprevious
diagnosis of the cancer at the time of the diagnosis.
Detailedmethods ofdatacollectionhave beendescribed
elsewhere (18).
Table 5 shows the result ofthe matched case-control
comparison when mortality was used as the outcome.
Exposureis definedbywhetherornotthepatientshave
been screened at least once within 10 years up to the
year the case was diagnosed. Case and controls were
matched by the year ofbirth, and 10 controls for each
case were chosen from the computer file ofresidents in
1965 when the screening started. Only one dead case in
thefileswasscreened. Theoddsratioofdyingofcervical
cancer for screened versus nonscreened women was es-
timated as 0.22.
Table 6 shows the result ofthe matched case-control
comparison when incidence ofinvasive cancer was used
as the outcome. For screen-detected cases, i.e., prev-
alent cases, controls were chosen from those who were
screened at the time of the diagnosis of the case. For
symptom-detected cases, i.e., incident cases, controls
were chosen from those who were not screened at the
time of diagnosis. For one particular screen-detected
case, only 2 controls were available, otherwise 10 con-
trols for each case could be chosen successfully. The
oddsratioofgettinginvasive cancerforscreenedversus
nonscreened women was estimated as 0.43 for screen-
detected cases and 0.41 for incident cases. The odds
Table 5. Distribution of matched sets of dead cases and their
controls according to screening history.'
1:10 Match Number of matched controls screened
Case 0 1 2 3 4 5 6 7 8 9 10 Total
Screened 1 0 0 0 0 0 0 0 0 0 0 1
Not screened 6 2 1 1 1 0 2 1 0 0 0 14
'From Sobue et al. (18). Odds ratio = 0.22 (95% CI = 0.03-1.95)
Table 6. Distribution of matched sets of invasive cancer cases
and their controls according to screening history by sets of
screen-detected and symptom-detected cases.8
Sets of screen-detected cases
1:2 Match Number ofmatched controls screened
Case 0 1 2 Total
Screened 0 0 0 0
Not screened 1 0 0 1
Number of matched controls screened
1:10 Match 0 1 2 3 4 5 6 7 8 9 10
Screened 0 0 0 0 0 0 0 0 0 3 1 4
Not screened 0 0 0 1 0 0 0 1 0 0 0 2
OR = 0.43 (95% CI = 0.05-3.71)
Sets of symptom-detected cases
Number of matched controls screened
1:10 Match 0 1 2 3 4 5 6 7 8 9 10
Screened 0 0 2 0 0 1 0 0 0 0 0 3
Not screened 6 3 2 0 2 1 2 2 0 0 0 18
OR = 0.41 (95% CI = 0.11-1.56)
aFrom Sobue et al. (18). OR, odds ratio. OR for both groups com-
bined = 0.41 (95% CI = 0.13-1.29)
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Table 7. Odds ratios (OR) of getting invasive cancer according
to the number of screening tests within 10 years.'
Number oftests
within 10 years OR 95% CI
None 1.00
Once 0.54 0.18 - 1.65
Twice or more 0.11 0.01 - 1.06
aFrom Sobue et al. (18). x2 for linearity = 4.06 (p < 0.05)
ratio for screen-detected cases is thought as an odds
ratio for prevalence, and the odds ratio for symptom-
detected cases as the odds ratio for incidence. If the
invasive period of the detectable predlinical phase is
almost equal to the unit of time, a year in this case,
then these ratios will be very similar and both types of
sets can be combined. The odds ratio for both groups
combined was estimated at 0.41.
Table 7 shows the odds ratios ofgettinginvasive cer-
vical cancer according to the number ofscreening tests
within 10 years. Compared to those patients who had
neverbeen screened, the odds ratios forbeing screened
once was 0.54, and being screened twice or more was
0.11. The trend for the linearity was statistically sig-
nificant.
Table8showstheoddsratiosaccordingtothenumber
of years since the last screening test. The odds ratios
for being screened 1 to 2 yr before was 0.27, 0.23 for 3
to 4 years, and 0.55 for 5 years or more.
Summarizing these findings, it was estimated that
78% of cervical cancer mortality and 59% of invasive
cervical cancer incidence among nonscreened women
could be prevented by cervical cancer screening. The
main problem of this study is all the estimated odds
ratios were not statistically significant. For example,
the powerto make odds ratio ofdying ofcervical cancer
statistically significant with 5% alpha error is 64%. In
order to make this power 80%, an additional 10 sets are
needed. Inthis town, however, about one ortwo deaths
ofcervical cancerhavebeenobservedperyearrecently,
so that we would have to follow 10 more years in order
to obtain statistically significant results. Considering
these facts, we decided to publish the report, empha-
sizing how the biases can be reduced in this study.
Study Design of a Case-Control
Study for Evaluating Lung Cancer
Screening in Japan
Lung cancer screening by chest X-ray for all partic-
ipants and sputum cytology for high-risk people have
beenconductedforseveralyearsinsome areasinJapan,
although the effectiveness of lung cancer screening on
the reduction of the mortality has never been estab-
lished. The results obtained fromthreerandomized con-
trolled trials conducted in the U.S. showed that the
effectiveness ofsputum cytology for high-risk groups is
minimal, if any, but the effectiveness of chest X-rays
Table 8. Odds ratios (OR) of getting invasive cancer according
to the
number of years since the last screening test.'
Years since
last test OR 95% CI
None 1.00
1-2 0.27 0.06 - 1.23
3-4 0.23 0.02 - 2.24
5 or more 0.55 0.13 - 2.29
aFrom Sobue et al. (18). x2 for linearity = 3.36 (p < 0.10).
was not directly investigated. The results from a case-
control study conducted recently in Berlin, DDR,
showed no reduction ofmortality oflungcancerinthose
who were screened by chest X-ray. However, since the
histologicdistributionisdifferentinthe DDR andJapan
and since the level of medical technology may also be
differentbetweenthetwocountries, resultsinthe DDR
may not be applied directly to Japan. It is also true,
however, that an evaluation oflung cancer screening in
terms ofmortality reduction has never been condleted
in Japan.
Looking at these facts, a case-control study for eval-
uating lung cancer screening was started lastyearwith
the support of Grants-in-Aid for cancer research from
the Ministry ofHealth and Welfare ofJapan. The prob-
lems when conducting a case-control study for evalu-
ating screenings for lung cancer are as follows: first,
the screening procedure is complicated and usually a
chest X-ray is taken for all cases and sputum cytology
is performed, only for high-risk groups; second, lung
cancer is a heterogeneous disease in terms of various
characteristics, and these may have to be divided into
subgroups when evaluating; third, chest X-ray exami-
nation is available in various facilities, so it is difficult
to collect complete information ofthe exposure; fourth,
the expected mortality reduction by screening may be
small, so a larger number of subjects are needed; and
finally, smoking can be a strong confounding factor.
In the current Japanese case-control study for eval-
uating lung cancer screening, cases are defined as all
patients who died from lung cancer between the ages
of 40 and 74. These cases were diagnosed after the
screening started and had lived in their area since the
year the screening started. Also, cases were limited to
high-risk groups for men and nonhigh-risk groups for
women to increase the efficiency ofthe study. Controls
were defined as anyone alive at the time ofdiagnosis of
the matched case who had no previous diagnosis oflung
cancer before the case was diagnosed, and who lived in
their area since the year the screening started. Also
controls were matched by sex, year of birth, and
whether they were a high-risk group or not. High-risk
groups were defined either as those who smoked ciga-
rettes20pack-years andwhowere40yearsoldormore,
or those who smoked cigarettes 30 pack-years and who
were 50 years old or more. These criteria were actually
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used for selecting people for sputum cytology in each
study area. Concerning the calculation of the sample
size, in order to make the odds ratio of0.75 statistically
significant with 5% a error and 20% ,B error, we esti-
matedthat600caseswith 5 controls foreachcasewould
be needed, assuming a 30% screening rate in a popu-
lation. So far, about 100 cases have been registered in
the study and results will be available at the end of
1990.
Biases and Applications of a Case-
Control Study for Evaluating Cancer
Screening
Leadtime bias and length bias are thebasicproblems
when survival is compared between screen-detected
and symptom-detected cases, and they should be con-
sidered also in a case-control study (19). Lead time is
defined as the interval between the time of detection
by screening and the time at which the disease would
have been diagnosed in the absence of screening. It
makes survival in screen-detected cases look better,
even if in effect there is no difference. In case-control
studies where mortality is used as the outcome, a lead
time bias exists; it makes the odds ratio lower if the
survival of the cases are observed only for a short pe-
riod. If the survival of most cases is observed for a
sufficiently long period this bias can be reduced. When
the incidence ofinvasive canceris used as the outcome,
a lead time bias does not exist. On the other hand, a
length bias refers to the fact that screening tests tend
to detect the slow-growing cancers selectively and miss
the rapid-growing cancers that are more likely to pre-
sent symptoms between screening examinations. In
case-control studies, patients who were diagnosed be-
fore the screening program started should be excluded
from the case series because they did not have any
chance to be screened. These patients tend to undergo
alongintervalbetween diagnosis and death; this means
there is a better prognosis of the disease. Therefore,
afterexcludingthesepatientseligible casesmayinclude
those who have rapidly growing cancers. Therefore, if
the study period used to collect cases is too short, the
odds ratio will be biased towards unity; this situation
is unfavorable for screened people. This type of bias
also can be reduced if the study period that is used to
collect cases is sufficiently long. Also, when using the
incidence of invasive cancer as the outcome, this type
ofbias is not a concern.
There arevarious sourcesfortheselectionbias, which
means different characteristics causing differences in
the mortality or incidence between screened and non-
screened people. First, ifrisk factors forthe cancer are
distributed differently between screened and non-
screened people, the mortality or incidence cannot be
simply compared in terms of the effectiveness of the
screening. For example, participants in cervical cancer
screening tend to have higher socioeconomic status,
while low socioeconomic status is one ofthe riskfactors
for cervical cancer. Therefore, the incidence ofcervical
cancer is already lower in screened women, even if no
effect from screening exists. However, as long as the
factors are known and related information can be ob-
tained in the study, this bias can be practically con-
trollable. Controls are taken by either matching the
collection ofdata or adjusting the analysis because the
number ofsubjects dealt with in a case-control study is
usuallysmall. Secondly, besidestheincidenceitself, the
characteristics ofthe cancer may be different between
screened and nonscreened people. For example, smok-
ing is an established risk factor for lung cancer and
increases the incidence ofthe disease. Also, smoking is
related to each histologic type; namely, it has a strong
relation to squamous and small cell carcinoma and a
weak relation to adenocarcinoma. Therefore, the his-
tologic distribution can be different between screened
and nonscreened people ifthe rate ofsmoking is differ-
ent between screened and nonscreened people. Again,
this is also practically controllable as long as the infor-
mation can be obtained. Third, since participants for
screening tend to be health-conscious, they may seek
medical care earlier than nonparticipants do when they
haveclinicalsymptoms. Thismayleadtooverestimation
ofthe effect ofthe screening. Also, the prognosis ofthe
cancer may be different because of the more careful
lifestyle of the screened people. These types of biases
cannot be controlled in a study design itself and addi-
tional information will be needed.
There are also various types of misclassification on
outcome and exposure, which can happen in a case-
controlstudy. Misclassification ontheoutcomecanoccur
as a false-positive case or a false-negative case. False-
positives cases occur if the diagnosis of the cancer is
more selectively applied to screened people. In order
to avoid this misclassification, cases should be carefully
reviewedtodeterminewhetherornottheclinicalcourse
is compatible with the cancer. On the otherhand, false-
negative cases occur if the diagnosis of the cancer is
missed selectively in nonscreened people. This israther
difficult to deal with and additional information such as
autopsy data will be needed from outside the study.
Misclassification on the exposure can occur as recall
bias, whichisoneofthemostimportantbiasestocontrol
in case-control studies. Recall bias meansthat cases are
more likely to recall some past exposure rather than
healthy controls. Besides this bias, it is often difficult
to recall an exact past screening history for both cases
and controls. Therefore, it is preferable to use the list
of cases stored in the medical facilities rather than the
data obtained from an interview. This measure can pre-
vent these problems, but conversely, screening tests
conducted in other facilities will be ignored. This type
ofproblem can be reduced if areas where few facilities
are involved in the screening test are chosen for study.
Summarizing the points discussed above, the merits
and drawbacks of a case-control study for evaluating
screening are listed compared to other types of ap-
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proaches, such as randomized controlled trials. The
merits of using a case-control study are as follows: re-
sults are quickly available; the studies are applicable
for screening that is already widespread; fewer ethical
problems arise whencompared to experimental studies;
a large number of study subjects are not needed, such
as in the cohort approach; and it is possible to control
known confounding factors as long as the related infor-
mation is available. Also, it is appropriate to evaluate
exposures occurring close to the outcome; screenings
that take place closer in time to the outcome are more
effective, and a retrospective approach can evaluate
these exposures easily. This makes it possible to eval-
uate optimal screening intervals from a case-control
study. On the other hand, there are also drawbacks in
a case-control study: the study is influenced by the con-
dition ofmaintenance ofthe past screeningrecords, and
it is sometimes difficult to choose appropriate controls;
also, it is impossible to control unknown confounding
factors.
A case-control study for evaluating screening can be
applied to various kinds ofsituations. It can be used to
evaluatetheeffectiveness ofscreeningsthatarealready
widespread to find an optimal screening schedule after
the effectiveness is established, or to monitor the qual-
ity ofroutine screening activity.
Recently, case-control studies are used more fre-
quently in various fields includingthe evaluation ofcan-
cerscreening. Although manymethodological problems
remain to be discussed, there are also sufficient reasons
for promoting the use of case-control studies for eval-
uating screening in the future.
The work cited in this article were partially supported by Grants-
in-Aid from the Ministry ofHealth and Welfare, Japan (62-4). Tables
3 to 8 were reprinted by permission of the copyright owner, the
Japanese Cancer Association.
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